SCHEMBL176508

SCHEMBL176508

C=C(C)C(=O)OCCC(C[N+](C)(C)C)OP(=O)(O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.38
TSHR P16473 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 1/20 0.33
MEN1 O00255 1/20 0.33
CYP1A2 P05177 1/20 0.33
HRH1 P35367 1/20 0.33
KMT2A Q03164 1/20 0.33
GALR3 O60755 1/20 0.33
MAPT P10636 1/20 0.33
BLM P54132 1/20 0.33
CHRM1 P11229 2/20 0.31
CHRM5 P08912 1/20 0.31
CHRM3 P20309 1/20 0.31
BTN3A1 O00481 1/20 0.30
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
TBXA2R P21731 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methacrylic Acid SCHEMBL3884365 0.96 SMN1; SMN2 (0.36) THRBTSHRSMN1; SMN2LMNAALDH1A1
SCHEMBL28251339 0.92 TSHR (0.48) THRBTSHRLMNAALDH1A1MEN1
SCHEMBL2944691 0.92 THRB (0.44) THRBTSHRSMN1; SMN2LMNAALDH1A1
SCHEMBL541861 0.92 TSHR (0.42) THRBTSHRSMN1; SMN2LMNAALDH1A1
Allylamine SCHEMBL28314014 0.91 THRB (0.33) THRBTSHRSMN1; SMN2LMNA
SCHEMBL541372 0.91 TSHR (0.44) THRBTSHRSMN1; SMN2LMNAALDH1A1
SCHEMBL541106 0.89 TSHR (0.47) THRBTSHRSMN1; SMN2LMNAPOLB
SCHEMBL541808 0.89 TSHR (0.47) THRBTSHRSMN1; SMN2LMNAPOLB
SCHEMBL28062034 0.89 TSHR (0.47) THRBTSHRSMN1; SMN2LMNAPOLB
SCHEMBL80350 0.89 THRB (0.36) THRBTSHRSMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713720-A2 HIGH-ENERGY-VIOLET-ABSORBING VINYLIC MONOMERS Alcon Inc. (CH) 2026-03-25 EP claimed
EP-4714453-A1 USE OF STRUCTURE FOR NUCLEIC ACID DELIVERY IN TREATMENT OF HEMATOPOIETIC TUMOR Japan Science and Technology Agency (JP) 2026-03-25 EP claimed
WO-2025029684-A1 LOW VOLUME RESUSCITANTS AND METHODS OF MAKING AND USING THE SAME UNIVERSITY OF WASHINGTON (US) 2025-02-06 WO claimed
WO-2024236526-A2 HIGH-ENERGY-VIOLET-ABSORBING VINYLIC MONOMERS ALCON INC. (CH) 2024-11-21 WO claimed
US-20240383865-A1 HIGH-ENERGY-VIOLET-ABSORBING VINYLIC MONOMERS ALCON INC (CH) 2024-11-21 US claimed
US-12097113-B2 Bioprosthetic valve and preparation method thereof SICHUAN UNIVERSITY (CN) 2024-09-24 US claimed
US-20240238325-A1 Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2024-07-18 US claimed
US-20240189121-A1 ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS COVIDIEN LP 2024-06-13 US claimed
EP-3666299-B1 ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS COVIDIEN LP (US) 2024-05-15 EP claimed
WO-2024051272-A1 METHOD FOR CONSTRUCTING HYDROPHILIC ANTIFOULING COATING ON SURFACE OF MEDICAL IMPLANTABLE MATERIAL 泰州度博迈医疗器械有限公司 2024-03-14 WO claimed
US-8252531-B2 Using biopolymer comprising phosphorylcholine-like groups to prevent non-specific hybridization of nucleotide sequence; drug screening NOF CORPORATION (JP) 2012-08-28 US claimed
US-20100203004-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER L'OREAL (FR) 2010-08-12 US claimed
US-20100094339-A1 COATING COMPOSITIONS COVIDIEN LP 2010-04-15 US claimed
EP-2120824-A1 COATING COMPOSITIONS Tyco Healthcare Group LP (US) 2009-11-25 EP claimed
WO-2008143654-A1 COATING COMPOSITIONS TYCO HEALTHCARE GROUP LP (US) 2008-11-27 WO claimed
EP-1764078-B1 Microcapsules with aqueous core and their use in cosmetic compositions OREAL (FR) 2008-05-14 EP claimed
EP-1764078-A1 Microcapsules with aqueous core and their use in cosmetic compositions L'OREAL (FR) 2007-03-21 EP claimed
EP-1206946-B1 MEDICAL MATERIALS AND PROCESS FOR PRODUCING THE SAME NOF CORP (JP) 2006-08-30 EP claimed
US-6828028-B1 Having surface treated with copolymer of such as ring opened glycidyl methacrylate and 2-(methacryloyloxy)ethyl-2-(tri-methylammonio)ethylphosphate; lubricity, blood compatible, safe, stable, durable NOF CORPORATION (JP) 2004-12-07 US claimed
EP-1206946-A1 MEDICAL MATERIALS AND PROCESS FOR PRODUCING THE SAME NOF CORPORATION (JP) 2002-05-22 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383865-A1 HIGH-ENERGY-VIOLET-ABSORBING VINYLIC MONOMERS VCL, HBS1L, SAAL1 THRB 1222/4885TSHR 2984/4885SMN1; SMN2 4643/4885
US-20240238325-A1 Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same HNRNPH3, RNASEH1, HNRNPA1 THRB 3469/4885TSHR 1640/4885SMN1; SMN2 796/4885
US-20100203004-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER PHOSPHO1, CUTA, SGMS1 THRB 3607/4885TSHR 3000/4885SMN1; SMN2 3042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.